Legend Biotech Corp Cash Flows From Used In Operations
Legend Biotech Corp (LEGN) reported Cash Flows From Used In Operations of -$138.36 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-11.
Financial Statements › Notes
ifrs-full:CashFlowsFromUsedInOperations · last filed 2025-08-11
- Legend Biotech Corp cash flows from used in operations for the quarter ending 2025-06-30 was -$32.07M.
- Legend Biotech Corp cash flows from used in operations for the quarter ending 2025-03-31 was -$106.29M, a 4558.31% decline year-over-year.
- Legend Biotech Corp cash flows from used in operations for the quarter ending 2024-12-31 was -$90.64M.
- Legend Biotech Corp cash flows from used in operations for the quarter ending 2024-09-30 was -$83.58M.
| Period end | Cash Flows From Used In Operations 3 month | Cash Flows From Used In Operations 6 month | Cash Flows From Used In Operations 9 month | Cash Flows From Used In Operations 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$32.07M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$138.36M 6-K · filed 2025-08-11 | -$228.99M derived: sum of 3 quarters · filed 2025-08-11 | -$312.57M derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | -$106.29M 6-K · filed 2025-05-13 | -$196.92M derived: sum of 2 quarters · filed 2025-05-13 | -$280.50M derived: sum of 3 quarters · filed 2025-05-13 | -$286.72M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-12-31 | -$90.64M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$174.22M derived: sum of 2 quarters · filed 2025-03-11 | -$180.43M derived: sum of 3 quarters · filed 2025-08-11 | -$178.05M 20-F · filed 2025-03-11 |
| 2024-09-30 | -$83.58M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$89.80M derived: sum of 2 quarters · filed 2025-08-11 | -$87.41M 6-K · filed 2024-11-12 | -$197.36M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-06-30 | -$6.22M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | -$3.83M 6-K · filed 2025-08-11 | -$113.78M derived: sum of 3 quarters · filed 2025-08-11 | -$190.50M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $2.38M 6-K · filed 2025-05-13 | -$107.57M derived: sum of 2 quarters · filed 2025-05-13 | -$184.28M derived: sum of 3 quarters · filed 2025-05-13 | -$294.13M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$109.95M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$186.67M derived: sum of 2 quarters · filed 2025-03-11 | -$296.51M derived: sum of 3 quarters · filed 2025-03-11 | -$439.46M 20-F · filed 2025-03-11 |
| 2023-09-30 | -$76.72M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | -$186.56M derived: sum of 2 quarters · filed 2024-11-12 | -$329.51M 6-K · filed 2024-11-12 | -$383.07M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$109.84M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | -$252.80M 6-K · filed 2024-08-09 | -$306.35M derived: sum of 3 quarters · filed 2025-03-11 | -$379.28M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | -$142.95M 6-K · filed 2024-05-13 | -$196.51M derived: sum of 2 quarters · filed 2025-03-11 | -$269.44M derived: sum of 3 quarters · filed 2025-03-11 | |
| 2022-12-31 | -$53.55M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$126.48M derived: sum of 2 quarters · filed 2025-03-11 | -$210.04M 20-F · filed 2025-03-11 | |
| 2022-09-30 | -$72.93M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | -$156.49M 6-K · filed 2023-11-20 | ||
| 2022-06-30 | -$83.56M 6-K · filed 2023-08-15 | |||
| 2021-12-31 | -$199.53M 20-F · filed 2024-03-19 | |||
| 2021-06-30 | -$84.40M 6-K · filed 2021-08-23 | |||
| 2020-12-31 | -$233.29M 20-F · filed 2023-03-30 | |||
| 2020-06-30 | -$103.11M 6-K · filed 2021-08-23 | |||
| 2019-12-31 | -$76.43M 20-F/A · filed 2023-02-17 | |||
| 2018-12-31 | $305.96M 20-F · filed 2021-04-02 |